Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Lilly's Evista Not Effective For Heart Disease, Preliminary Results Show

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company plans to submit an sNDA for raloxifene to treat invasive breast cancer by the end of 2006.

You may also be interested in...



Lilly Gets Its Wish: STAR Results Show Evista Reduces Breast Cancer Risk

Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.

Lilly Gets Its Wish: STAR Results Show Evista Reduces Breast Cancer Risk

Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.

Lilly Pleads Guilty To Off-Label Evista Promotion

The company will pay a $36 mil. fine for promoting the osteoporosis drug for reduction in breast cancer risk.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS063993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By